Xcout Intel
Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, which agreed to merge with Regeneron Pharmaceuticals.
Subscribe to see Decibel Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Decibel Therapeutics, Inc. at a glance
Decibel Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $87.1M across the 2 funding rounds on record. Its most recent funding round raised $54.8M in November 2020. Xcout tracks 18 named people at Decibel Therapeutics, Inc., including Leonard S. Schleifer (Board co-Chair, President and Chief Executive Officer).
Decibel Therapeutics, Inc. leadership
- Leonard S. SchleiferBoard co-Chair, President and Chief Executive Officer
- George D. YancopoulosBoard co-Chair, President and Chief Scientific Officer
- Chris FenimoreExecutive Vice President, Finance and Chief Financial Officer
- Rick HallSenior Vice President, Human Resources and Chief Human Resources Officer
- Brook JenningsSenior Vice President, Global Immunology Commercial Business Unit
- Christina ChanSenior Vice President, Corporate Affairs
12 more named people on record for Decibel Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Decibel Therapeutics, Inc. funding rounds
At least $87.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $54.8M | — | |
| SEC Form D filing | $32.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Decibel Therapeutics, Inc. competitors
A few of Decibel Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Regeneron is a biopharmaceutical company that researches, develops, and commercializes medicines for people with serious diseases. Utilizing proprietary technologies in antibodies and genetic medicines, the company serves patients globally by addressing conditions in areas such as oncology, immunology, ophthalmology, and rare diseases.
Rgenta Therapeutics, Inc. is a biotechnology research company headquartered in Woburn, Massachusetts, that focuses on unlocking the therapeutic potential of disease-relevant RNA targets.
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Dewpoint Therapeutics is an integrated drug discovery platform company headquartered in Boston, Massachusetts. The firm leverages advanced biotechnology to translate condensate biology into novel medicines for various therapeutic areas.
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Get Decibel Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Decibel Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Decibel Therapeutics, Inc. in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access